Neuroendocrine and Rare Tumor Advances: A New and Promising TRAIL Emerges.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 35491654.
- Also identified by DOI 10.1158/1078-0432.CCR-22-0120 and PMC identifier 9069729.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
ONC201 is an oral selective antagonist of the dopamine D2 receptor and direct activator of caseinolytic protease P. In a phase II study, ONC021 was shown to be well tolerated with notable efficacy in patients with the rare neuroendocrine neoplasms pheochromocytomas-paragangliomas, although biomarkers for activity remain to be elucidated. See related article by Anderson et al., p. 1773.
Medical subject headings
- Adrenal Gland Neoplasms
- Desmoplastic Small Round Cell Tumor
- Neuroendocrine Tumors
- Paraganglioma
- Pheochromocytoma